Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$2.30
-$0.08(-3.90%)
At close: 4:00 PM EST
$2.30
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$2.07 - $12.50
Previous CloseN/A
Volume52.61K
Average Volume (3M)3.06M
Market Cap
$19.67M
Enterprise Value-$332.89K
Total Cash (Recent Filing)$9.35M
Total Debt (Recent Filing)$331.00K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 18, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding3,997,002
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$8.00Price Target Upside247.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSeaStar's reported gross margins above 90% reflect highly favorable unit economics for its SCD device and consumables. Persistent product-level margins create structural operating leverage: as volumes scale, incremental revenue can flow directly to improving operating profitability and cash generation.
Commercial Traction & Customer GrowthThe addition of seven hospitals and a growing installed base demonstrates repeatable early commercial adoption and clinical interest. A widening customer footprint and reported repeat orders provide a foundation to scale sales, shorten adoption cycles, and convert clinical validation into more predictable revenue.
Low Financial LeverageVery low debt and a small debt-to-equity ratio reduce fixed financing obligations and insolvency risk. This cleaner capital structure gives management flexibility to pursue trial completion and commercialization via equity, partnerships, or internal cash, limiting near-term interest burdens.
Bears Say
High Cash BurnSeaStar's persistent negative operating and free cash flow of roughly -$13.7M TTM signals significant runway pressure. Continued cash consumption will likely require external financing or partnerships, increasing dilution risk and potentially constraining strategic choices if revenue scaling lags.
Small Absolute Revenue BaseAlthough percentage growth is strong, the absolute commercial base remains tiny (Q1 $495k), insufficient to cover fixed R&D and G&A. Reliance on limited pediatric/ultra-rare volumes means scaling revenue materially depends on broader clinical adoption and reimbursement progress.
Clinical & Regulatory Enrollment RiskWith ~58% of pivotal enrollment complete, remaining patient accrual and site activations are critical. Delays or enrollment shortfalls and uncertain FDA pathways could push back pivotal readouts, increase funding needs and postpone broader commercialization, creating structural timing and approval risk.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $12.50 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $19.67M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on May 13, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.075.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.97.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,997,002 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial and clinical momentum: notable YoY revenue growth (+69%), seven new hospital customers in Q1, completion of the SAVE Registry enrollment (50 patients), substantial trial progress (198/339 enrolled, ~58%) and a stronger cash position (+~79% YoY). Management emphasized high gross margins (>90%), disciplined operating spend and active FDA engagement on potential accelerated pathways. Offsetting this progress are the small absolute revenue base ($495k Q1), continued quarterly net losses (~$3.5M), dependence on ultra-rare pediatric case flow for adoption, ongoing enrollment and regulatory risks, and notable share dilution. Overall, the call presents meaningful early-stage commercial validation and clinical progress but also highlights typical execution and regulatory risks for a clinical-stage medical device company.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$8.00
▲(247.83% Upside)
Technical Analysis
Ownership Overview
3.79% Insiders
1.32% Mutual Funds
<0.01% Other Institutional Investors
94.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---